Has Namita Goyal, MD received payments from drug or device companies?

Yes. Drug and device makers reported $174,008 in general payments to Namita Goyal, MD across 209 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Namita Goyal, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Namita Goyal, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Namita Goyal, MD

Neuromuscular Medicine · Orange, CANPI 1336116904

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (48.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Argenx US, Inc. at 33.8% of the total. 2025 is the largest year on record at $51,393, 2.1 times the $25,055 reported in 2019.

$174,008in general payments, 2019–2025

Across 209 payments — averaging $832.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Argenx US, Inc.$59K
CSL Behring$44K
Amgen$23K
AstraZeneca$14K
Sanofi$12K
Octapharma USA, Inc.$7K
plus $15K from 12 others

$1,370,619in research payments, 2019–2025

Across 184 payments — averaging $7449.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Janssen Research & Development, LLC$324K
Genentech, Inc.$237K
AstraZeneca$226K
PTC Therapeutics, Inc.$138K
Sanofi$122K
Orion Corporation$64K
plus $259K from 9 others

What the payments were for

Consulting fees$73,37342%
Speaking & faculty fees$84,68449%
Travel & lodging$9,2615%
Food & beverage$6,6584%
Education$320%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Argenx US, Inc.	65	$58,744
CSL Behring	34	$44,421
Amgen	23	$23,076
AstraZeneca(2 entities)	30	$13,638
Sanofi	6	$12,127
Octapharma USA, Inc.	10	$6,968
Tanabe Pharma America, Inc.	9	$4,610
UCB, Inc.	5	$3,502
Biogen	1	$3,065
UCB SA	2	$2,840
Grifols USA, LLC	12	$283
Genentech, Inc.	2	$243
Catalyst Pharmaceuticals, Inc.	2	$164
Johnson & Johnson	2	$162
Sarepta Therapeutics, Inc.	2	$117
Boston Scientific	1	$27
Takeda Pharmaceuticals U.S.A., Inc.	1	$19
Travere Therapeutics, Inc.	2	$1

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Hizentra$44,060
VYVGART$43,780
LUMIZYME$12,077
VYVGART HYTRULO$11,649
UPLIZNA$8,104
OCTAGAM IMMUNE GLOBULIN (HUMAN)$5,666
Radicava$4,507
Privigen$4,501
SOLIRIS$4,337
ULTOMIRIS$2,206
PANZYGA$1,000
Enspryng$149
EVRYSDI$149
FIRDAPSE$131
Zilbrysq$105

How this compares

$174,008 in reported general payments places this provider in the 85th percentile of 44 neuromuscular medicine providers in California.

See all neuromuscular medicine providers in California →

Medicare billing

Part B allowed, 2024

$60,763

Medicare patients

182

Services billed

559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Radicava OrsEdaravone	73	$1,028,518
RadicavaEdaravone	25	$307,679
GammaplexImmun Glob G(Igg)/Gly/Iga 0-50	26	$271,735
RelyvrioSod Phenylbutyrat/Taurursodiol	12	$149,087
NuedextaDextromethorphan Hbr/Quinidine	35	$57,513
Riluzole	47	$4,093
Atropine Sulfate	15	$527
MethotrexateMethotrexate Sodium	15	$459
Duloxetine Hcl	20	$457
Gabapentin	33	$410
Baclofen	17	$296
Nortriptyline Hcl	11	$164
Prednisone	28	$89

Paid to pharmacies, not to this prescriber.

Other neuromuscular medicine in Orange

Ali HabibOrange$445K
Tahseen MozaffarOrange$428K
Jay HanOrange$126K
Khalid AlrasheedOrange$75K
Jeffrey MullenOrange$13K
Jonathan CauchiOrange$895
Mona Rezaei MirghaedOrange$673
Samir MacwanRancho Mirage$983K
Jeffrey RosenfeldFresno$361K
John DayStanford$294K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →